SCHEMBL24257767

SCHEMBL24257767

CCOC(=O)CNC(=O)c1ncc(-c2cnn(-c3ccc(F)cc3)c2)c(C)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
EGLN1 Q9GZT9 4/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
GRM4 Q14833 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
VEGFA P15692 1/20 0.36
FLT1 P17948 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257828 0.91 EGLN1 (0.43) NPC1RAB9ALMNAALDH1A1KDM4E
SCHEMBL24257699 0.91 HPGD (0.44) NPC1RAB9ALMNAALDH1A1TP53
SCHEMBL24257554 0.89 EGLN1 (0.48) EGLN1GRM4VEGFAFLT1EGLN3
SCHEMBL24257724 0.85 RIPK2 (0.39) NPC1RAB9ALMNAALDH1A1KDM4E
SCHEMBL24257796 0.85 EGLN1 (0.47) NPC1RAB9ALMNAALDH1A1KDM4E
SCHEMBL24257842 0.83 EGLN1 (0.52) NPC1RAB9AKDM4EEGLN1VEGFA
SCHEMBL26259968 0.83 ALDH1A1 (0.42) NPC1RAB9ALMNAALDH1A1TP53
SCHEMBL26259694 0.81 EGLN1 (0.55) EGLN1VEGFAFLT1EGLN3
SCHEMBL24257530 0.81 EGLN1 (0.47) EGLN1VEGFAFLT1EGLN3
SCHEMBL24257797 0.80 HSP90AA1 (0.41) NPC1RAB9ALMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 NPC1 4011/4885RAB9A 739/4885LMNA 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.